MedImmune

MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.

Address: Milstein Building, Granta Park , Cambridge
Postcode: CB21 6GH
Country: United Kingdom
Website: http://www.medimmune.com
Membership type:Founder Member

MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline.   It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.

MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden

MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented.  With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.

1 Humira is a registered trademark of AbbVie Inc.
2 Benlysta is a registered trademark of GlaxoSmithKline

MedImmune is the global biologics R&D arm of AstraZeneca

MedImmune is the global biologics research and development arm of AstraZeneca, focused on pioneering research and exploring novel mechanisms and pathways across key therapeutic areas.

Medimmune partners with the National Cancer Institute to advance oncology research

MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has entered into two umbrella Cooperative Research and Development Agreements (CRADAs) with the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), that are focused on immunotherapy and tumor targeted therapies for cancer.

21 January 2015Read in full

MedImmune hosts a DMU seminar for details of a new biopharmaceutical distance learning course

MedImmune hosts a DMU seminar for details of a new biopharmaceutical distance learning course

De Montfort University’s Quality by Design group invites you to attend the launch event at MedImmune on Granta Park next Tuesday (January 13) for their new distance learning module in Quality by Design.

8 January 2015Read in full

Quality by Design for Biopharmaceuticals: progress and opportunities

Quality by Design for Biopharmaceuticals: progress and opportunities

De Montfort University’s Quality by Design group invites you to attend the launch event at MedImmune on Granta Park for their new distance learning module in Quality by Design for Biopharmaceuticals.

10 December 2014Read in full

MedImmune presents positive Phase IIB data for rheumatoid arthritis treatment

MedImmune, the global biologics research and development arm of AstraZeneca, today announced positive results from a Phase IIb study of mavrilimumab, a first-in-class investigational monoclonal antibody for the treatment of rheumatoid arthritis (RA). Study results are being presented in several abstracts at the American College of Rheumatology (ACR) 2014 Annual Meeting taking place in Boston, MA.

17 November 2014Read in full

MedImmune presents promising new data in systemic lupus

MedImmune, the global biologics research and development arm of AstraZeneca, today announced it will be presenting positive data from a Phase IIb study on sifalimumab, a novel monoclonal antibody targeting interferon being investigated for treatment in patients with moderate to severe systemic lupus erythematosus (SLE or lupus), at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, MA.

17 November 2014Read in full

Quality by Design for biopharmaceuticals: progress and opportunities

Quality by Design for biopharmaceuticals: progress and opportunities

De Montfort University’s Quality by Design group invites you to attend the launch event at MedImmune on Granta Park for its new distance learning module in Quality by Design for Biopharmaceuticals.

10 November 2014Read in full

MedImmune strengthens immuno-oncology capabilities with acquisition of Definiens

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue.

4 November 2014Read in full

MedImmune in-licenses acute coronary syndrome biologic research program from Shionogi

MedImmune, the global biologics research and development arm of AstraZeneca, and Japanese drug discovery-based pharmaceutical company Shionogi & Co., Ltd., announced today that they have entered a global license agreement under which MedImmune will in-license Shionogi’s novel preclinical biologic program for the potential treatment of acute coronary syndrome (ACS).

8 October 2014Read in full

Benralizumab Phase II COPD study published in 'The Lancet Respiratory Medicine'

AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa study evaluating its novel investigational monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease (COPD).

8 September 2014Read in full

Groundbreaking collaborative clinical trial launched

The Lung-MAP trial uses a multi-drug, targeted screening approach to match patients with promising new cancer treatments based on their unique tumor profiles.

16 June 2014Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6